Corrigendum to: Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130). (17th January 2020) - Iwata, Hiroji; Inoue, Kenichi; Kaneko, Koji; Ito, Yoshinori; Tsugawa, Koichiro; Hasegawa, Ayumi; Nakagawa, Shintaro; Kuratomi, Hiroyasu; Tamura, Kenji